Initially used primarily for managing type 2 diabetes, these drugs have recently gained attention for their weight loss benefits
If ePA leads to more patients receiving GLP-1 therapy on schedule (versus some patients dropping after a difficult manual PA), then short-term costs might rise
Liraglutide and Semaglutide are both GLP-1 receptor agonists used in the treatment of type 2 diabetes as well as weight loss in non-diabetic individuals
Do these programs accept insurance
However, no direct head-to-head trials comparing these agents for liver fat reduction have been conducted, so definitive comparative conclusions cannot yet be drawn
Therefore, from a practical point of view, we can conclude that: the vast majority of nevi are, at worse, clinicopathological simulators and not precursors to melanoma